BPC-157 Compounding Pharmacy: How to Get It

Key Takeaways

The FDA placed BPC-157 in Category 2 in January 2025, which means compounding pharmacies under sections 503A and 503B are no longer permitted to produce it
Before this change, getting BPC-157 from a compounding pharmacy was straightforward — doctor writes a prescription, pharmacy compounds it
Some clinics and pharmacies are still navigating the regulatory gray area, while industry groups are actively challenging the FDA’s authority
Legal alternatives exist, including oral BPC-157 supplements and other peptides that remain on the Category 1 (permitted) list

How Compounding Pharmacies Used to Supply BPC-157
What the FDA’s Category 2 Designation Means
503A vs 503B Pharmacies and BPC-157
Can Any Compounding Pharmacy Still Make BPC-157?
How to Find a Compounding Pharmacy for Peptides
The Prescription Process
Cost of BPC-157 from a Compounding Pharmacy
Legal Challenges and What May Change
Alternatives Still Available Through Compounding
Quality and Safety: What to Verify
FAQ
Sources

How Compounding Pharmacies Used to Supply BPC-157

For years, the standard pathway to BPC-157 was relatively simple. A physician would evaluate your condition — whether that was a tendon injury, chronic gut inflammation, or post-surgical recovery — and write a prescription. A compounding pharmacy would then produce the peptide in the prescribed dose and formulation, typically as a lyophilized powder for reconstitution and injection.

This worked because compounding pharmacies operate under a legal framework that allows them to create customized medications not commercially available. BPC-157 has no FDA-approved commercial product, making it a natural fit for compounding.

The peptide itself has a strong research foundation. Animal studies have demonstrated BPC-157’s ability to accelerate healing of Achilles tendons (full recovery in transected rat tendons), protect gastric mucosa, reduce inflammation, and support nerve regeneration [1][2]. In early-phase human trials for inflammatory bowel disease, it showed no reported toxicity at tested doses [3].

Compounding pharmacies were the bridge between this promising research and patient access. That bridge has been narrowed considerably.

What the FDA’s Category 2 Designation Means

In January 2025, the FDA published its interim policy on compounding using bulk drug substances. This document created three categories for substances used in compounding [4]:

Category 1: Substances that can be used in compounding. These have been evaluated and the FDA has no current safety objections. Peptides like Sermorelin remain in this category.

Category 2: Substances that cannot be used in compounding. The FDA has evaluated these and determined they present safety concerns or don’t meet the requirements for compounding. BPC-157 landed here.

Category 3: Substances still under evaluation. The FDA hasn’t made a final determination yet.

For BPC-157 specifically, the FDA’s reasoning centered on the lack of human clinical data sufficient to establish a safety profile for compounded use, combined with concerns about the proliferation of unregulated peptide products [4].

This was part of a broader FDA peptide reclassification that affected dozens of peptides. TB-500 (thymosin beta-4 fragment), CJC-1295, Ipamorelin, AOD-9604, and others were also placed in Category 2 [5]. The full picture of peptide legality has become significantly more complex.

503A vs 503B Pharmacies and BPC-157

Understanding the difference between these two types of compounding pharmacies matters for anyone trying to access peptide therapy.

503A pharmacies are traditional compounding pharmacies. They fill individual prescriptions from licensed prescribers for specific patients. Your local compounding pharmacy is likely a 503A facility. Under the FDA’s Category 2 designation, these pharmacies are no longer permitted to use BPC-157 as a bulk drug substance [4].

503B outsourcing facilities are larger-scale operations that can produce compounded drugs without individual prescriptions. They supply clinics, hospitals, and healthcare facilities. These also fall under the Category 2 restriction for BPC-157 [6].

For a full comparison of how these pharmacy types differ in practice, quality standards, and regulatory oversight, see our 503A vs 503B compounding pharmacy guide.

The practical impact: regardless of which type of compounding pharmacy you’re working with, the FDA’s position is that BPC-157 should not be compounded. Some pharmacies are complying. Others are not. And the legal battles are ongoing.

Can Any Compounding Pharmacy Still Make BPC-157?

This is the question everyone asks. The honest answer is complicated.

The FDA’s position is clear: BPC-157 is Category 2 and should not be compounded under 503A or 503B [4][5].

Enforcement is another matter. The FDA’s guidance is technically an “interim policy,” not a final rule. Some legal experts argue this creates ambiguity about enforcement authority. Several compounding pharmacy trade groups and individual pharmacies have filed legal challenges [7].

Some clinics still offer BPC-157. A search of telehealth peptide providers in early 2026 shows that some clinics continue to advertise BPC-157 prescriptions. Whether their source pharmacies are operating within legal bounds is a question each provider should be able to answer transparently.

State-level variation exists. Compounding pharmacy regulations involve both federal and state oversight. Some state boards of pharmacy have not yet aligned their enforcement with the FDA’s Category 2 list, creating temporary gaps.

The bottom line: If a compounding pharmacy is still making BPC-157, they’re either interpreting the regulations differently than the FDA, challenging them legally, or not yet in compliance. As a patient, you should understand which situation applies.

How to Find a Compounding Pharmacy for Peptides

Even though BPC-157 access is restricted, many other peptide therapies remain available through compounding pharmacies. Here’s how to find a quality one:

Start with your prescribing physician. Doctors who specialize in peptide therapy maintain relationships with reputable compounding pharmacies. A peptide clinic near you or a telehealth peptide provider will have established pharmacy partnerships.

Verify accreditation. Look for pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) or the Accreditation Commission for Health Care (ACHC). These certifications indicate adherence to quality standards above the legal minimum.

Check for state licensing. The pharmacy should be licensed in both their home state and your state (for shipped prescriptions). This is verifiable through state board of pharmacy websites.

Ask about testing. Quality compounding pharmacies perform potency testing, sterility testing (for injectables), endotoxin testing, and stability testing on their products. Ask for certificates of analysis.

503B facilities generally have stricter oversight. If you have the option, a 503B outsourcing facility typically operates under more rigorous quality standards, including FDA inspection. See our compounding pharmacy peptides guide for more on what to look for.

The Prescription Process

Getting any peptide from a compounding pharmacy follows a standard medical pathway:

1. Medical consultation. You need a licensed prescriber — MD, DO, NP, or PA — to evaluate your condition and determine if peptide therapy is appropriate. This can happen in-person at a peptide therapy clinic or through a telehealth consultation.

2. Prescription written. The prescriber specifies the peptide, dose, formulation (injectable, oral, topical), quantity, and refills. For BPC-157 specifically, typical protocols in the literature use 250-500 mcg/day for injection or 500-1,000 mcg/day for oral administration [8].

3. Pharmacy compounds the medication. The pharmacy sources the bulk drug substance, compounds it per the prescription, performs quality testing, and ships it to you (or you pick it up locally).

4. You receive instructions. For injectables, this includes how to reconstitute peptides, injection technique, storage requirements, and where to inject.

5. Follow-up care. Your prescriber monitors your progress and adjusts the protocol as needed.

For peptides that remain available through compounding (see Alternatives section below), this process works exactly as described.

Cost of BPC-157 from a Compounding Pharmacy

When BPC-157 was readily available through compounding, typical pricing looked like this:

Component	Cost Range
Initial physician consultation	$99-$300
BPC-157 vial (5mg, ~20-day supply at 250mcg/day)	$100-$200
BPC-157 vial (10mg, ~20-day supply at 500mcg/day)	$150-$300
Bacteriostatic water	$10-$20
Syringes and supplies	$15-$30/month
Follow-up consultations	$50-$150 each

Monthly all-in cost: $200-$450 depending on dosage and provider.

These prices reflected pharmacy-grade, tested products from licensed facilities. If you see BPC-157 advertised significantly below these ranges, question the source and quality.

For the broader picture of peptide therapy pricing, including currently available options, see our peptide therapy cost guide. Keep in mind that insurance generally does not cover peptide therapy, so these are out-of-pocket costs.

Legal Challenges and What May Change

The FDA’s Category 2 designation for BPC-157 is not necessarily permanent. Several developments could change things:

Active litigation. Compounding pharmacy trade organizations, including the Outsourcing Facilities Association and Alliance for Pharmacy Compounding, have challenged aspects of the FDA’s bulk drug substance lists. Court rulings could force the FDA to reconsider certain Category 2 placements [7].

Congressional interest. Several members of Congress have expressed concern about the FDA’s approach to compounding regulation, particularly around patient access issues. Legislative action could override or modify the FDA’s categorization framework.

New clinical data. If human clinical trials generate sufficient safety and efficacy data, BPC-157 could potentially be moved to Category 1 or even pursued as an FDA-approved drug product.

Industry adaptation. Some manufacturers are developing modified versions of BPC-157 (like arginate salt formulations) that may fall outside the compounding restriction framework.

The regulatory situation is fluid. What’s true in March 2026 may shift by the end of the year. Working with a knowledgeable provider who stays current on these changes is your best strategy.

Alternatives Still Available Through Compounding

If you were using BPC-157 from a compounding pharmacy and need alternatives, several options remain in Category 1:

Sermorelin: A growth hormone-releasing hormone analog that supports tissue repair indirectly by boosting your body’s growth hormone production. Well-studied, widely available through compounding, and covered by some of the same recovery-focused protocols.

GHK-Cu: A copper peptide with documented wound healing, anti-inflammatory, and tissue remodeling properties. Available in injectable and topical forms from compounding pharmacies.

Thymosin Alpha-1: An immune-modulating peptide that supports healing through immune system optimization. Still available through many compounding pharmacies depending on their interpretation of current guidelines.

Oral BPC-157: Arginate salt formulations sold as supplements bypass the compounding restriction entirely. While absorption differs from injectable forms, oral BPC-157 has shown efficacy in animal studies, particularly for gut-related conditions.

Combination approaches: Many clinicians are achieving results comparable to BPC-157 monotherapy by combining available peptides. A peptide protocol that stacks GHK-Cu with a growth hormone secretagogue can target multiple healing pathways simultaneously.

Quality and Safety: What to Verify

Whether you’re getting BPC-157 or any other peptide from a compounding pharmacy, quality control matters enormously. Here’s your checklist:

Certificate of Analysis (COA). Every batch should have one. It should show purity (typically >98% for peptides), identity confirmation (usually by mass spectrometry), and endotoxin levels (for injectables).

Sterility testing. Injectable peptides must be sterile. Ask about the pharmacy’s sterility testing protocols and whether they test each batch or rely on process validation.

Beyond-use dating. Compounded medications have expiration dates (called “beyond-use dates”). For reconstituted peptides, this is typically 28-30 days when refrigerated. If a pharmacy claims their reconstituted peptide lasts 6 months, be skeptical.

Storage and shipping. Peptides are temperature-sensitive. They should be shipped with cold packs and you should store them refrigerated. A pharmacy that ships peptides in a padded envelope without temperature control is cutting corners.

Adverse event reporting. Reputable pharmacies have systems for tracking and reporting adverse events. This is legally required for 503B facilities and good practice for 503A.

If you’re concerned about peptide safety in general, the single biggest risk factor is product quality — not the peptide itself. A pure, properly dosed peptide from a quality pharmacy is fundamentally different from an untested powder purchased online.

FAQ

Can I still get BPC-157 from a compounding pharmacy in 2026?▼

The FDA’s position is that BPC-157 should not be compounded under 503A or 503B since its January 2025 Category 2 designation. Some pharmacies may still offer it while legal challenges are pending, but compliant pharmacies have discontinued it. Ask your provider directly about their pharmacy’s legal position and sourcing.

What’s the difference between a 503A and 503B compounding pharmacy?▼

A 503A pharmacy fills individual patient prescriptions and is primarily regulated by state boards. A 503B outsourcing facility can produce larger batches, ships to healthcare facilities, and faces direct FDA oversight including inspections. Both are currently restricted from compounding BPC-157 under the Category 2 designation.

How do I know if a compounding pharmacy is legitimate?▼

Look for PCAB or ACHC accreditation, verify state licensing, ask for certificates of analysis on peptide products, and confirm they perform sterility testing on injectables. Legitimate pharmacies are transparent about their quality processes and can provide documentation on request.

Is oral BPC-157 from a supplement company the same as compounded BPC-157?▼

No. Compounded BPC-157 (when it was available) was produced under pharmaceutical standards with potency and sterility testing. Oral BPC-157 supplements are manufactured under dietary supplement regulations (cGMP), which have different quality standards. The active compound is the same, but the formulation, testing rigor, and delivery method differ. The oral arginate salt form is specifically designed for gastric stability [3].

What peptides can I still get from a compounding pharmacy?▼

Several therapeutic peptides remain in Category 1 or are otherwise available through compounding. These include Sermorelin, GHK-Cu (non-injectable), certain weight loss peptides, and others. The list changes as the FDA continues its review process. A peptide doctor who stays current on regulations can guide you to the best available options for your specific needs.

Sources

Chang CH, et al. “Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.” J Orthop Res. 2003;21(6):976-82. PubMed: 14554208
Seiwerth S, et al. “Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.” Front Pharmacol. 2021;12:627533. DOI: 10.3389/fphar.2021.627533
Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Curr Pharm Des. 2011;17(16):1612-32. PubMed: 21548867
FDA. “Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A.” January 2025. FDA.gov
SafeHG. “FDA’s Overreach on Compounded Peptides: Legal Battles and How Clinics Can Push Back.” February 2026. safehg.com
Fagron Academy. “Interim 503A and 503B Bulks Lists New Revisions.” 2025. fagronacademy.us
Holt Law. “Regulatory Alert: The Legal Status of BPC-157 in Compounding and Clinical Practice.” 2025. djholtlaw.com
PeptideDeck. “BPC-157: Complete Research Guide.” 2026. peptidedeck.com